SlideShare a Scribd company logo
1
2Q11 Earnings Release
         August, 11th, 2011




                              2
Highlights in the Period


• Net income rose by 333.6% quarter-over-quarter and totaled R$ 9.5 million, with a 1.4% net margin;


• Consolidated gross revenues grew 7.5% year-over-year, totaling R$ 779.4 million;


• Highlight for the health and beauty category, whose sales increased for the sixth quarter in a row. There was a steep year-
over-year increase of 87.3%;


• The positive operating cash flow amounted to R$ 50.0 million in 2Q11, or 7.6% of the net operating revenue;


• There was 5.8-day reduction in the cash cycle. This decrease resulted in a drop in working capital of about R$ 45.4
million;


• Operating (administrative, selling and logistics) expenses fell by 1.4 percentage point year-over-year and totaled 7.5% of
the net operating revenue;


• Sales through electronic orders hit a record high and accounted for 68.6% of total sales in 2Q11.



                                                                                                                                3   3
Gross Revenues Evolution
                (R$ Million)




                  778.8            779.4


724.7




2Q10              1Q11             2Q11




                                           4   4
Gross Revenues Breakdown


(R$ Million)                    2Q11    2Q10    Chg. %   1Q11    Chg. %

Branded                         512.2   477.5    7.3%    507.1   1.0%
Generic                          45.7    50.3   -9.1%     54.5   -16.1%
OTC                             141.3   143.8   -1.7%    148.7   -4.9%
Health and Beauty Products       53.9    28.8   87.3%     47.6   13.1%
Hospitals + Vaccines             26.3    24.3    7.9%     21.0   25.3%

Total                           779.4   724.7    7.5%    778.8   0.1%




                                                                          5   5
Market Share Evolution (%)



                          11.5    11.7
                                             10.9*
                                                         10.2*
       9.6                                                            9.5*   9.9*
                                                                                            9.0*




      2006                2007    2008       2009        2010         2Q10   1Q11          2Q11

*Excluding the similar’s effect                                                Source: IMS and Profarma




                                                                                                          6   6
Gross Profit and Revenues from Services to Suppliers
                 (R$ million and as % Net Revenues)




   12.3%
                                                        10.7%
                                9.6%



    25.1
                                                         27.4
                                24.0



    49.7
                                39.1                     42.9




    2Q10                       1Q11                     2Q11

Gross Profit   Revenues from Services to Suppliers    Gross Profit Margin (%)




                                                                                7   7
Operating Expenses
       (R$ million and as % Net Revenues)



8.9%
                    7.7%                    7.5%


53.8
                     50.7                   49.5




2Q10                1Q11                    2Q11




                                                   8   8
Ebitda and Ebitda Margin
       (R$ million and as % Net Revenues)




3.6%                                        3.2%

                    1.7%



21.8
                                            20.7




                     10.9




2Q10                 1Q11                   2Q11




                                                   9   9
Net Financial Expenses
       (R$ million and as % Net Revenues)



1.9%
                                            1.3%
                     1.1%


11.8


                                            8.8

                      7.2




2Q10                1Q11                    2Q11




                                                   10 10
Net Profit
       (R$ million and as % Net Revenues)




1.9%
                                            1.4%

                     0.3%

11.4

                                            9.5




                      2.2




2Q10                1Q11                    2Q11




                                                   11 11
CASH FLOW

(R$ Million)                                             2Q11     2Q10      Chg. %   1Q11     Chg. %

Cash Flow Generated / (Used) in Operating Activities     50,0      46,8     6,9%     (80,2)      -
  Internal Cash Generation                               19,8      17,6     12,7%    10,4     90,6%
 Operating Assets Variation                              30,2      29,2     3,5%     (90,6)      -
     Trade Accounts Receivable                           37,3      28,3     31,7%    22,9     62,6%
     Inventories                                         46,3      92,4     -50,0%   (30,8)      -
     Suppliers                                           (48,7)   (105,2)   53,7%    (74,7)   34,8%
     Other Items                                         (4,6)     13,7       -      (8,1)    42,9%

Cash Flow (Used) in Investing Activities                 (1,8)     (1,9)    3,3%     (1,3)    -43,2%

Cash Flow Generated / (Used) by Financing Activities     (51,0)   (53,7)    5,1%     81,1        -

Net Increase / (Decrease) in Cash                        (2,8)     (8,8)    68,5%    (0,4)    -659,2%




                                                                                                        12 12
Cycle IFRS Basis

                                        2Q10 1Q11 2Q11
  Cash Cycle (Days) *                    66.3    64.5   60.4

  Accounts Receivable (1)                42.2    43.9   39.4
  Inventories (2)                        48.8    59.3   53.1
  Accounts Payable (3)                   24.8    38.7   32.0

* Average
(1)   Average of Gross Revenues in the Quarter
(2)   Average of COGS in the Quarter
(3)   Average of COGS in the Quarter




                                                               13 13
Indebtedness: Net Debt and Net Debt / Ebitda*
                                        (R$ million)




                                           2.7x                 2.2x
                     1.4x



                                          194.8

                                                               157.1
                    132.5




                    2Q10                  1Q11                 2Q11

* Ebitda = Accumulated last 12 months




                                                                       14 14
Capex
       (R$ million and % as Net Revenues)




0.3%                 0.2%                   0.3%




1.9                                         1.9
                      1.3




2Q10                 1Q11                   2Q11




                                                   15 15
Operating Indicators

                Service Level                                         Logistics E.P.M.
        (Units served/ Units requested)                               (Errors per Million)



89.6%               89.5%                                                                    337.0
                                          88.6%




                                                                          144.0
                                                              121.0




2Q10                1Q11                  2Q11                2Q10         1Q11              2Q11




                                                                                                     16 16
Profarma vs Ibovespa - % (2Q11)

115




110




105




100

                                                                                                   97
 95



                                                                                                   91
 90




 85
  31-Mar-11   15-Apr-11   30-Apr-11              15-May-11          30-May-11   14-Jun-11   29-Jun-11



                                      Ibovespa               Profarma




                                                                                                        17 17
Analyst Coverage

Company          Analyst                           Telephone           E-mail


                 Javier Martinez de Olcoz Cerdan   (1 212) 761-4542    javier.martinez.olcoz@morganstanley.com
Morgan Stanley
                 Clarissa Berman                   (55 11) 3048-6214   clarissa.berman@morganstanley.com


Merrill Lynch    Alexandre Pizano                  (55 11) 2188-4024   alexandre.pizano@baml.com

Credit Suisse    Marcel Moraes                     (55 11) 3841-6302   marcel.moraes@credit-suisse.com


                 Juliana Rozenbaum                 (55 11) 3073-3035   juliana.rozenbaum@itausecurities.com
Itaú BBA
                 Marcio Osako                      (55 11) 3073-3040   marcio.osako@itausecurities.com


Banco Fator      Iago Whately                      (55 11) 3049-9480   iwhately@bancofator.com.br

Raymond James    Guilherme Assis                   (55 11) 3513-8706   guilherme.assis@raymondjames.com

BTG Pactual      João Carlos dos Santos            (55 11) 3383-2384   joaocarlos.santos@btgpactual.com




                                                                                                                 18 18
19

More Related Content

What's hot

Earnings Release 2 Q07
Earnings Release 2 Q07Earnings Release 2 Q07
Earnings Release 2 Q07
Profarma
 
Earnings Release 3 Q07
Earnings Release 3 Q07Earnings Release 3 Q07
Earnings Release 3 Q07
Profarma
 
Earnings Release 1 Q07
Earnings Release 1 Q07Earnings Release 1 Q07
Earnings Release 1 Q07
Profarma
 
Profarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 EngProfarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 Eng
profarma1
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 final
Profarma
 
Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 Presentation
Profarma
 
Paragon Shipping Q4 2012 results presentation
Paragon Shipping Q4 2012 results presentationParagon Shipping Q4 2012 results presentation
Paragon Shipping Q4 2012 results presentation
TradeWindsnews
 
Wessanen q3 2012 press release
Wessanen q3 2012 press releaseWessanen q3 2012 press release
Wessanen q3 2012 press release
Klaus Arntz
 
Presentation 1Q12 | Locamerica
Presentation 1Q12 | LocamericaPresentation 1Q12 | Locamerica
Presentation 1Q12 | Locamerica
locamerica
 
4 q11 presentation results
4 q11 presentation results4 q11 presentation results
4 q11 presentation results
rimagazineluiza
 
raytheon Q4 Earnings Presentation
raytheon Q4 Earnings Presentationraytheon Q4 Earnings Presentation
raytheon Q4 Earnings Presentation
finance12
 

What's hot (14)

Apresentacao Call Result 1 T08 Eng Final
Apresentacao Call Result 1 T08 Eng FinalApresentacao Call Result 1 T08 Eng Final
Apresentacao Call Result 1 T08 Eng Final
 
Earnings Release 2 Q07
Earnings Release 2 Q07Earnings Release 2 Q07
Earnings Release 2 Q07
 
Earnings Release 3 Q07
Earnings Release 3 Q07Earnings Release 3 Q07
Earnings Release 3 Q07
 
Earnings Release 1 Q07
Earnings Release 1 Q07Earnings Release 1 Q07
Earnings Release 1 Q07
 
Profarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 EngProfarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 Eng
 
Investors' meeting 2 q08 results
Investors' meeting   2 q08 resultsInvestors' meeting   2 q08 results
Investors' meeting 2 q08 results
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 final
 
Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 Presentation
 
Paragon Shipping Q4 2012 results presentation
Paragon Shipping Q4 2012 results presentationParagon Shipping Q4 2012 results presentation
Paragon Shipping Q4 2012 results presentation
 
Wessanen q3 2012 press release
Wessanen q3 2012 press releaseWessanen q3 2012 press release
Wessanen q3 2012 press release
 
Presentation 1Q12 | Locamerica
Presentation 1Q12 | LocamericaPresentation 1Q12 | Locamerica
Presentation 1Q12 | Locamerica
 
FY 2011 IFRS Results
FY 2011 IFRS ResultsFY 2011 IFRS Results
FY 2011 IFRS Results
 
4 q11 presentation results
4 q11 presentation results4 q11 presentation results
4 q11 presentation results
 
raytheon Q4 Earnings Presentation
raytheon Q4 Earnings Presentationraytheon Q4 Earnings Presentation
raytheon Q4 Earnings Presentation
 

Viewers also liked

Apimec 1T14
Apimec 1T14Apimec 1T14
Apimec 1T14
Profarma
 
Teleconferência 4T13 e ano 2013
Teleconferência 4T13 e ano 2013Teleconferência 4T13 e ano 2013
Teleconferência 4T13 e ano 2013
Profarma
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 Presentation
Profarma
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 Presentation
Profarma
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08
Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
Profarma
 
Conference Call 3Q14
Conference Call 3Q14Conference Call 3Q14
Conference Call 3Q14
Profarma
 
Profarma Apresentação 3Q10
Profarma Apresentação 3Q10Profarma Apresentação 3Q10
Profarma Apresentação 3Q10
Profarma
 
Earnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationEarnings Release 4Q08 Presentation
Earnings Release 4Q08 Presentation
Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
Profarma
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
Profarma
 
Apresentação pt_1t14
Apresentação pt_1t14Apresentação pt_1t14
Apresentação pt_1t14
Profarma
 
Profarma apimec
Profarma apimecProfarma apimec
Profarma apimec
Profarma
 

Viewers also liked (18)

Profarma reunião pública vf
Profarma reunião pública vfProfarma reunião pública vf
Profarma reunião pública vf
 
Apimec 1T14
Apimec 1T14Apimec 1T14
Apimec 1T14
 
Teleconferência 4T13 e ano 2013
Teleconferência 4T13 e ano 2013Teleconferência 4T13 e ano 2013
Teleconferência 4T13 e ano 2013
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 Presentation
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 Presentation
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Conference Call 3Q14
Conference Call 3Q14Conference Call 3Q14
Conference Call 3Q14
 
Profarma Apresentação 3Q10
Profarma Apresentação 3Q10Profarma Apresentação 3Q10
Profarma Apresentação 3Q10
 
Earnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationEarnings Release 4Q08 Presentation
Earnings Release 4Q08 Presentation
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
 
Apresentação pt_1t14
Apresentação pt_1t14Apresentação pt_1t14
Apresentação pt_1t14
 
Profarma apimec
Profarma apimecProfarma apimec
Profarma apimec
 
Profarma - 2T16
Profarma - 2T16Profarma - 2T16
Profarma - 2T16
 
Profarma - 2Q16
Profarma - 2Q16Profarma - 2Q16
Profarma - 2Q16
 
Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma Aquisição Rosario
Profarma Aquisição Rosario
 
Profarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma Rosario Chain Acquisition
Profarma Rosario Chain Acquisition
 

Similar to Profarma apresentação 2 q11

Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11
Profarma
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12
Profarma
 
Profarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 EngProfarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 Eng
profarma1
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
Profarma
 
Earnings Release 2Q09 Presentation
Earnings Release 2Q09 PresentationEarnings Release 2Q09 Presentation
Earnings Release 2Q09 Presentation
Profarma
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 Presentation
Profarma
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
Profarma
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
Profarma
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12
Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
Profarma
 
arnings Release 2Q07 Presentation
arnings Release 2Q07 Presentationarnings Release 2Q07 Presentation
arnings Release 2Q07 Presentation
Profarma
 
Earnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationEarnings Release 1Q07 Presentation
Earnings Release 1Q07 Presentation
Profarma
 
Earnings Release 4 Q07
Earnings Release 4 Q07Earnings Release 4 Q07
Earnings Release 4 Q07
Profarma
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 Presentation
Profarma
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
Profarma
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results
Embraer RI
 

Similar to Profarma apresentação 2 q11 (19)

Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12
 
Profarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 EngProfarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 Eng
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
 
Earnings Release 2Q09 Presentation
Earnings Release 2Q09 PresentationEarnings Release 2Q09 Presentation
Earnings Release 2Q09 Presentation
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 Presentation
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
arnings Release 2Q07 Presentation
arnings Release 2Q07 Presentationarnings Release 2Q07 Presentation
arnings Release 2Q07 Presentation
 
Earnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationEarnings Release 1Q07 Presentation
Earnings Release 1Q07 Presentation
 
Earnings Release 4 Q07
Earnings Release 4 Q07Earnings Release 4 Q07
Earnings Release 4 Q07
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 Presentation
 
Presentation CCR - 3Q09
Presentation CCR - 3Q09Presentation CCR - 3Q09
Presentation CCR - 3Q09
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results
 
Idea Cellular
Idea  CellularIdea  Cellular
Idea Cellular
 
2Q 2011 Results Conference Call
2Q 2011 Results Conference Call 2Q 2011 Results Conference Call
2Q 2011 Results Conference Call
 

More from Profarma (20)

Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma Day - 13.12.2017
Profarma Day - 13.12.2017
 
Apresentação 3Q17
Apresentação 3Q17Apresentação 3Q17
Apresentação 3Q17
 
Apresentação 3T17
Apresentação 3T17Apresentação 3T17
Apresentação 3T17
 
Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17
 
Apresentação 2T17
Apresentação 2T17Apresentação 2T17
Apresentação 2T17
 
Apresentação 1Q17
Apresentação 1Q17Apresentação 1Q17
Apresentação 1Q17
 
Apresentação 1T17
Apresentação 1T17Apresentação 1T17
Apresentação 1T17
 
4Q16 Presentation
4Q16 Presentation4Q16 Presentation
4Q16 Presentation
 
Apresentação 4T16
Apresentação 4T16Apresentação 4T16
Apresentação 4T16
 
Profarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma - 3Q16 earnings release
Profarma - 3Q16 earnings release
 
Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16
 
Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016
 
1 t16 varejo
1 t16 varejo1 t16 varejo
1 t16 varejo
 
1 q16
1 q161 q16
1 q16
 
4 t15
4 t154 t15
4 t15
 
4 q15
4 q154 q15
4 q15
 
3 q15
3 q153 q15
3 q15
 
3 t15
3 t153 t15
3 t15
 
Teleconferência 2Q15
Teleconferência 2Q15Teleconferência 2Q15
Teleconferência 2Q15
 
Teleconferência 2T15
Teleconferência 2T15Teleconferência 2T15
Teleconferência 2T15
 

Recently uploaded

what is the future of Pi Network currency.
what is the future of Pi Network currency.what is the future of Pi Network currency.
what is the future of Pi Network currency.
DOT TECH
 
NO1 Uk Divorce problem uk all amil baba in karachi,lahore,pakistan talaq ka m...
NO1 Uk Divorce problem uk all amil baba in karachi,lahore,pakistan talaq ka m...NO1 Uk Divorce problem uk all amil baba in karachi,lahore,pakistan talaq ka m...
NO1 Uk Divorce problem uk all amil baba in karachi,lahore,pakistan talaq ka m...
Amil Baba Dawood bangali
 

Recently uploaded (20)

where can I sell pi coins at the best rate (Market Price)
where can I sell pi coins at the best rate (Market Price)where can I sell pi coins at the best rate (Market Price)
where can I sell pi coins at the best rate (Market Price)
 
Jio Financial service Multibagger 2024 from India stock Market
Jio Financial service  Multibagger 2024 from India stock MarketJio Financial service  Multibagger 2024 from India stock Market
Jio Financial service Multibagger 2024 from India stock Market
 
Monthly Market Risk Update: May 2024 [SlideShare]
Monthly Market Risk Update: May 2024 [SlideShare]Monthly Market Risk Update: May 2024 [SlideShare]
Monthly Market Risk Update: May 2024 [SlideShare]
 
how to sell pi coins at high rate quickly.
how to sell pi coins at high rate quickly.how to sell pi coins at high rate quickly.
how to sell pi coins at high rate quickly.
 
Isios-2024-Professional-Independent-Trustee-Survey.pdf
Isios-2024-Professional-Independent-Trustee-Survey.pdfIsios-2024-Professional-Independent-Trustee-Survey.pdf
Isios-2024-Professional-Independent-Trustee-Survey.pdf
 
The new type of smart, sustainable entrepreneurship and the next day | Europe...
The new type of smart, sustainable entrepreneurship and the next day | Europe...The new type of smart, sustainable entrepreneurship and the next day | Europe...
The new type of smart, sustainable entrepreneurship and the next day | Europe...
 
when officially can i withdraw my pi Network coins.
when officially can i withdraw my pi Network coins.when officially can i withdraw my pi Network coins.
when officially can i withdraw my pi Network coins.
 
what is the best method to sell pi coins in 2024
what is the best method to sell pi coins in 2024what is the best method to sell pi coins in 2024
what is the best method to sell pi coins in 2024
 
how can I sell/buy bulk pi coins securely
how can I sell/buy bulk pi coins securelyhow can I sell/buy bulk pi coins securely
how can I sell/buy bulk pi coins securely
 
how can I send my pi coins to Binance exchange
how can I send my pi coins to Binance exchangehow can I send my pi coins to Binance exchange
how can I send my pi coins to Binance exchange
 
how can i make money selling pi coins in 2024
how can i make money selling pi coins in 2024how can i make money selling pi coins in 2024
how can i make money selling pi coins in 2024
 
how to sell pi coins in Canada, Uk and Australia
how to sell pi coins in Canada, Uk and Australiahow to sell pi coins in Canada, Uk and Australia
how to sell pi coins in Canada, Uk and Australia
 
how do I get a legit pi buyer in the internet (2024)
how do I get a legit pi buyer in the internet (2024)how do I get a legit pi buyer in the internet (2024)
how do I get a legit pi buyer in the internet (2024)
 
what is the future of Pi Network currency.
what is the future of Pi Network currency.what is the future of Pi Network currency.
what is the future of Pi Network currency.
 
Most Profitable Cryptocurrency to Invest in 2024.pdf
Most Profitable Cryptocurrency to Invest in 2024.pdfMost Profitable Cryptocurrency to Invest in 2024.pdf
Most Profitable Cryptocurrency to Invest in 2024.pdf
 
Economics and Economic reasoning Chap. 1
Economics and Economic reasoning Chap. 1Economics and Economic reasoning Chap. 1
Economics and Economic reasoning Chap. 1
 
how can I sell my pi coins for cash in a pi APP
how can I sell my pi coins for cash in a pi APPhow can I sell my pi coins for cash in a pi APP
how can I sell my pi coins for cash in a pi APP
 
9th issue of our inhouse magazine Ingenious May 2024.pdf
9th issue of our inhouse magazine Ingenious May 2024.pdf9th issue of our inhouse magazine Ingenious May 2024.pdf
9th issue of our inhouse magazine Ingenious May 2024.pdf
 
Summary of financial results for 1Q2024
Summary of financial  results for 1Q2024Summary of financial  results for 1Q2024
Summary of financial results for 1Q2024
 
NO1 Uk Divorce problem uk all amil baba in karachi,lahore,pakistan talaq ka m...
NO1 Uk Divorce problem uk all amil baba in karachi,lahore,pakistan talaq ka m...NO1 Uk Divorce problem uk all amil baba in karachi,lahore,pakistan talaq ka m...
NO1 Uk Divorce problem uk all amil baba in karachi,lahore,pakistan talaq ka m...
 

Profarma apresentação 2 q11

  • 1. 1
  • 2. 2Q11 Earnings Release August, 11th, 2011 2
  • 3. Highlights in the Period • Net income rose by 333.6% quarter-over-quarter and totaled R$ 9.5 million, with a 1.4% net margin; • Consolidated gross revenues grew 7.5% year-over-year, totaling R$ 779.4 million; • Highlight for the health and beauty category, whose sales increased for the sixth quarter in a row. There was a steep year- over-year increase of 87.3%; • The positive operating cash flow amounted to R$ 50.0 million in 2Q11, or 7.6% of the net operating revenue; • There was 5.8-day reduction in the cash cycle. This decrease resulted in a drop in working capital of about R$ 45.4 million; • Operating (administrative, selling and logistics) expenses fell by 1.4 percentage point year-over-year and totaled 7.5% of the net operating revenue; • Sales through electronic orders hit a record high and accounted for 68.6% of total sales in 2Q11. 3 3
  • 4. Gross Revenues Evolution (R$ Million) 778.8 779.4 724.7 2Q10 1Q11 2Q11 4 4
  • 5. Gross Revenues Breakdown (R$ Million) 2Q11 2Q10 Chg. % 1Q11 Chg. % Branded 512.2 477.5 7.3% 507.1 1.0% Generic 45.7 50.3 -9.1% 54.5 -16.1% OTC 141.3 143.8 -1.7% 148.7 -4.9% Health and Beauty Products 53.9 28.8 87.3% 47.6 13.1% Hospitals + Vaccines 26.3 24.3 7.9% 21.0 25.3% Total 779.4 724.7 7.5% 778.8 0.1% 5 5
  • 6. Market Share Evolution (%) 11.5 11.7 10.9* 10.2* 9.6 9.5* 9.9* 9.0* 2006 2007 2008 2009 2010 2Q10 1Q11 2Q11 *Excluding the similar’s effect Source: IMS and Profarma 6 6
  • 7. Gross Profit and Revenues from Services to Suppliers (R$ million and as % Net Revenues) 12.3% 10.7% 9.6% 25.1 27.4 24.0 49.7 39.1 42.9 2Q10 1Q11 2Q11 Gross Profit Revenues from Services to Suppliers Gross Profit Margin (%) 7 7
  • 8. Operating Expenses (R$ million and as % Net Revenues) 8.9% 7.7% 7.5% 53.8 50.7 49.5 2Q10 1Q11 2Q11 8 8
  • 9. Ebitda and Ebitda Margin (R$ million and as % Net Revenues) 3.6% 3.2% 1.7% 21.8 20.7 10.9 2Q10 1Q11 2Q11 9 9
  • 10. Net Financial Expenses (R$ million and as % Net Revenues) 1.9% 1.3% 1.1% 11.8 8.8 7.2 2Q10 1Q11 2Q11 10 10
  • 11. Net Profit (R$ million and as % Net Revenues) 1.9% 1.4% 0.3% 11.4 9.5 2.2 2Q10 1Q11 2Q11 11 11
  • 12. CASH FLOW (R$ Million) 2Q11 2Q10 Chg. % 1Q11 Chg. % Cash Flow Generated / (Used) in Operating Activities 50,0 46,8 6,9% (80,2) - Internal Cash Generation 19,8 17,6 12,7% 10,4 90,6% Operating Assets Variation 30,2 29,2 3,5% (90,6) - Trade Accounts Receivable 37,3 28,3 31,7% 22,9 62,6% Inventories 46,3 92,4 -50,0% (30,8) - Suppliers (48,7) (105,2) 53,7% (74,7) 34,8% Other Items (4,6) 13,7 - (8,1) 42,9% Cash Flow (Used) in Investing Activities (1,8) (1,9) 3,3% (1,3) -43,2% Cash Flow Generated / (Used) by Financing Activities (51,0) (53,7) 5,1% 81,1 - Net Increase / (Decrease) in Cash (2,8) (8,8) 68,5% (0,4) -659,2% 12 12
  • 13. Cycle IFRS Basis 2Q10 1Q11 2Q11 Cash Cycle (Days) * 66.3 64.5 60.4 Accounts Receivable (1) 42.2 43.9 39.4 Inventories (2) 48.8 59.3 53.1 Accounts Payable (3) 24.8 38.7 32.0 * Average (1) Average of Gross Revenues in the Quarter (2) Average of COGS in the Quarter (3) Average of COGS in the Quarter 13 13
  • 14. Indebtedness: Net Debt and Net Debt / Ebitda* (R$ million) 2.7x 2.2x 1.4x 194.8 157.1 132.5 2Q10 1Q11 2Q11 * Ebitda = Accumulated last 12 months 14 14
  • 15. Capex (R$ million and % as Net Revenues) 0.3% 0.2% 0.3% 1.9 1.9 1.3 2Q10 1Q11 2Q11 15 15
  • 16. Operating Indicators Service Level Logistics E.P.M. (Units served/ Units requested) (Errors per Million) 89.6% 89.5% 337.0 88.6% 144.0 121.0 2Q10 1Q11 2Q11 2Q10 1Q11 2Q11 16 16
  • 17. Profarma vs Ibovespa - % (2Q11) 115 110 105 100 97 95 91 90 85 31-Mar-11 15-Apr-11 30-Apr-11 15-May-11 30-May-11 14-Jun-11 29-Jun-11 Ibovespa Profarma 17 17
  • 18. Analyst Coverage Company Analyst Telephone E-mail Javier Martinez de Olcoz Cerdan (1 212) 761-4542 javier.martinez.olcoz@morganstanley.com Morgan Stanley Clarissa Berman (55 11) 3048-6214 clarissa.berman@morganstanley.com Merrill Lynch Alexandre Pizano (55 11) 2188-4024 alexandre.pizano@baml.com Credit Suisse Marcel Moraes (55 11) 3841-6302 marcel.moraes@credit-suisse.com Juliana Rozenbaum (55 11) 3073-3035 juliana.rozenbaum@itausecurities.com Itaú BBA Marcio Osako (55 11) 3073-3040 marcio.osako@itausecurities.com Banco Fator Iago Whately (55 11) 3049-9480 iwhately@bancofator.com.br Raymond James Guilherme Assis (55 11) 3513-8706 guilherme.assis@raymondjames.com BTG Pactual João Carlos dos Santos (55 11) 3383-2384 joaocarlos.santos@btgpactual.com 18 18
  • 19. 19